𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease

✍ Scribed by Karl Kieburtz

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
649 KB
Volume
33
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A controlled trial of piracetam in intel
A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease
✍ Mary Sano; Yaakov Stern; Karen Marder; Richard Mayeux 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

## Abstract Twenty patients with Parkinson's disease and marked intellectual impairment or dementia participated in a double‐blind placebo controlled trial of the nootropic, piracetam. A standardized neurological examination, a neuropsychological test battery, and a functional scale, The Sickness I

Treatment of insomnia in Parkinson's dis
Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo
✍ Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Michael Gara; Karina Bi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 1 views

## Abstract Parkinson's disease (PD) is a common neurodegenerative disease affecting up to 1 million individuals in the United States. Sleep disturbances, typically in sleep maintenance, are found in up to 88% of these individuals and are associated with a variety of poor outcomes. Despite being co

Randomized controlled trial of memantine
Randomized controlled trial of memantine in dementia associated with Parkinson's disease
✍ Iracema Leroi; Ross Overshott; E. Jane Byrne; Emily Daniel; Alistair Burns 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 1 views

## Abstract The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD. This was a 22‐week trial of 25 participants with a

Randomized placebo-controlled trial of d
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease
✍ Iracema Leroi; Jason Brandt; Stephen G. Reich; Constantine G. Lyketsos; Stephen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Abstract ## Objective To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD). ## Methods Using a randomized, double‐blind, placebo‐controlled design, nine patients rec

Twice-daily, low-dose pramipexole in ear
Twice-daily, low-dose pramipexole in early Parkinson's disease: A randomized, placebo-controlled trial
✍ Karl Kieburtz; The Parkinson Study Group PramiBID Investigators 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 1 views

## Abstract To compare the safety and efficacy of low dosages of pramipexole given twice daily (bid) in early Parkinson's disease (PD) with those of a standard 3 times daily (tid) regimen in a randomized, double‐blind, placebo controlled trial involving 311 early PD patients not receiving dopaminer

A controlled trial of remacemide hydroch
A controlled trial of remacemide hydrochloride in Huntington's disease
✍ Dr. Karl Kieburtz; Andrew Feigin; Michael McDermott; Peter Como; David Abwender; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 450 KB 👁 1 views

## Abstract We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate receptor ion‐channel blocker, remacemide hydrochloride, in 31 independently ambulatory patients (18 men, 13 women) with Huntington's disease (HD). Subjects were rand